Pier L Zinzani Selected Research

Pier L Zinzani Research Topics

Disease

5	B-Cell Lymphoma (Lymphoma, B Cell) 01/2024 - 01/2003
5	Neoplasms (Cancer) 01/2024 - 01/2012
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2023 - 08/2006
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 07/2023 - 08/2011
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 02/2023 - 11/2002
3	Lymphoma (Lymphomas) 10/2015 - 11/2002
2	Neutropenia 07/2023 - 01/2018
2	Hairy Cell Leukemia 01/2021 - 10/2015
1	Atrial Fibrillation 07/2023
1	Hemorrhage 07/2023
1	Hypertension (High Blood Pressure) 07/2023
1	Infections 07/2023
1	Lymphocytosis 07/2023
1	Hematologic Neoplasms (Hematological Malignancy) 01/2023
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2022
1	Disease Progression 01/2022
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2020
1	Hodgkin Disease (Hodgkin's Disease) 01/2018
1	Febrile Neutropenia 01/2018
1	Exanthema (Rash) 10/2015
1	Arthralgia (Joint Pain) 10/2015
1	Arthritis (Polyarthritis) 10/2015
1	T-Cell Lymphoma (Lymphoma, T Cell) 10/2015
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2012
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2012
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2012
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 08/2011

Drug/Important Bio-Agent (IBA)

7	Rituximab (Mabthera)FDA Link 02/2023 - 11/2002
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 11/2002
3	Vincristine (Oncovin)FDA LinkGeneric 10/2015 - 11/2002
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2012 - 11/2002
2	Agammaglobulinaemia Tyrosine KinaseIBA 07/2023 - 01/2022
2	VemurafenibIBA 01/2021 - 10/2015
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2018 - 01/2003
2	Lenalidomide (CC 5013)FDA Link 11/2011 - 08/2011
2	Prednisone (Sone)FDA LinkGeneric 01/2003 - 11/2002
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2024
1	axicabtagene ciloleucelIBA 01/2024
1	venetoclaxIBA 07/2023
1	pirtobrutinibIBA 07/2023
1	CT-P10IBA 02/2023
1	Biosimilar PharmaceuticalsIBA 02/2023
1	Circulating Tumor DNAIBA 11/2022
1	Complement System Proteins (Complement)IBA 11/2022
1	ibrutinibIBA 01/2022
1	Bendamustine Hydrochloride FDA Link 01/2022
1	loncastuximab tesirineIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2021
1	ibritumomab tiuxetan (Zevalin)FDA Link 01/2020
1	Dacarbazine (DIC)FDA LinkGeneric 01/2018
1	Brentuximab VedotinIBA 01/2018
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2018
1	Immunoconjugates (Immunoconjugate)IBA 01/2018
1	Vinblastine (Vinblastine Sulfate)FDA Link 01/2018
1	purineIBA 10/2015
1	Prednisolone (Predate)FDA LinkGeneric 10/2015
1	Histone Deacetylase InhibitorsIBA 10/2015
1	fludarabineIBA 01/2012
1	Biomarkers (Surrogate Marker)IBA 11/2011
1	epratuzumabIBA 08/2006
1	Methotrexate (Mexate)FDA LinkGeneric 01/2003
1	Transcription Factors (Transcription Factor)IBA 01/2003
1	Etoposide (VP 16)FDA LinkGeneric 11/2002
1	CD20 AntigensIBA 11/2002
1	Monoclonal AntibodiesIBA 11/2002

Therapy/Procedure

8	Therapeutics 07/2023 - 11/2002
5	Drug Therapy (Chemotherapy) 01/2024 - 11/2002
1	Transplantation 01/2024
1	Duration of Therapy 07/2023
1	Organ Transplantation 01/2023
1	Hematopoietic Stem Cell Transplantation 01/2023
1	Precision Medicine 11/2022
1	Radioimmunotherapy 01/2018
1	Aftercare (After-Treatment) 10/2015
1	Drug Tapering 10/2015
1	Immunotherapy 08/2006
1	Radiotherapy 01/2003
1	Salvage Therapy 11/2002
1	Stem Cell Transplantation 11/2002